Muyldermans Serge
Muyldermans Serge
Verified email at vub.ac.be
Title
Cited by
Cited by
Year
Naturally occurring antibodies devoid of light chains
C Hamers-Casterman, T Atarhouch, S Muyldermans, G Robinson, ...
Nature 363 (6428), 446-448, 1993
30371993
Nanobodies: natural single-domain antibodies
S Muyldermans
Annual review of biochemistry 82, 775-797, 2013
14052013
Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies
M Arbabi Ghahroudi, A Desmyter, L Wyns, R Hamers, S Muyldermans
FEBS letters 414 (3), 521-526, 1997
9271997
Single domain camel antibodies: current status
S Muyldermans
Reviews in molecular Biotechnology 74 (4), 277-302, 2001
9072001
A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins
U Rothbauer, K Zolghadr, S Muyldermans, A Schepers, MC Cardoso, ...
Molecular & Cellular Proteomics 7 (2), 282-289, 2008
6652008
Single‐domain antibody fragments with high conformational stability
M Dumoulin, K Conrath, A Van Meirhaeghe, F Meersman, K Heremans, ...
Protein Science 11 (3), 500-515, 2002
6362002
Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains
S Muyldermans, T Atarhouch, J Saldanha, J Barbosa, R Hamers
Protein Engineering, Design and Selection 7 (9), 1129-1135, 1994
6241994
Targeting and tracing antigens in live cells with fluorescent nanobodies
U Rothbauer, K Zolghadr, S Tillib, D Nowak, L Schermelleh, A Gahl, ...
Nature methods 3 (11), 887-889, 2006
6212006
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme
A Desmyter, TR Transue, MA Ghahroudi, MHD Thi, F Poortmans, ...
Nature structural biology 3 (9), 803-811, 1996
6091996
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies
E De Genst, K Silence, K Decanniere, K Conrath, R Loris, J Kinne, ...
Proceedings of the National Academy of Sciences 103 (12), 4586-4591, 2006
5982006
Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies
M Lauwereys, MA Ghahroudi, A Desmyter, J Kinne, W Hölzer, E De Genst, ...
The EMBO journal 17 (13), 3512-3520, 1998
5731998
Camelid immunoglobulins and nanobody technology
S Muyldermans, TN Baral, VC Retamozzo, P De Baetselier, E De Genst, ...
Veterinary immunology and immunopathology 128 (1-3), 178-183, 2009
4972009
A general protocol for the generation of Nanobodies for structural biology
E Pardon, T Laeremans, S Triest, SGF Rasmussen, A Wohlkönig, A Ruf, ...
Nature protocols 9 (3), 674-693, 2014
4592014
Modulation of protein properties in living cells using nanobodies
A Kirchhofer, J Helma, K Schmidthals, C Frauer, S Cui, A Karcher, ...
Nature structural & molecular biology 17 (1), 133-138, 2010
4582010
Efficient cancer therapy with a nanobody-based conjugate
V Cortez-Retamozo, N Backmann, PD Senter, U Wernery, P De Baetselier, ...
Cancer research 64 (8), 2853-2857, 2004
4582004
General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold
C Vincke, R Loris, D Saerens, S Martinez-Rodriguez, S Muyldermans, ...
Journal of Biological Chemistry 284 (5), 3273-3284, 2009
4322009
Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains
S Muyldermans, C Cambillau, L Wyns
Trends in biochemical sciences 26 (4), 230-235, 2001
4042001
β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae
KE Conrath, M Lauwereys, M Galleni, A Matagne, JM Frère, J Kinne, ...
Antimicrobial agents and chemotherapy 45 (10), 2807-2812, 2001
3892001
Comparison of llama VH sequences from conventional and heavy chain antibodies
KB Vu, MA Ghahroudi, L Wyns, S Muyldermans
Molecular immunology 34 (16-17), 1121-1131, 1997
3871997
Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy
B Van de Broek, N Devoogdt, A D’Hollander, HL Gijs, K Jans, L Lagae, ...
ACS nano 5 (6), 4319-4328, 2011
3552011
The system can't perform the operation now. Try again later.
Articles 1–20